Canaccord Genuity reissued their buy rating on shares of DexCom, Inc. (NASDAQ:DXCM) in a research report released on Tuesday morning.

Other equities analysts also recently issued reports about the company. B. Riley assumed coverage on DexCom in a research report on Sunday, October 2nd. They set a neutral rating and a $97.00 target price on the stock. Wedbush reaffirmed an outperform rating and issued a $112.00 target price (up from $100.00) on shares of DexCom in a report on Wednesday, November 2nd. Zacks Investment Research cut DexCom from a buy rating to a hold rating in a report on Thursday, November 3rd. Leerink Swann reaffirmed an outperform rating and issued a $100.00 target price (down from $115.00) on shares of DexCom in a report on Thursday, November 3rd. Finally, Oppenheimer Holdings, Inc. raised DexCom from a market perform rating to an outperform rating and set a $84.00 target price on the stock in a report on Monday, December 19th. Three investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. DexCom currently has a consensus rating of Buy and an average price target of $88.67.

Shares of DexCom (NASDAQ:DXCM) traded up 26.8056% during trading on Tuesday, hitting $85.7333. The stock had a trading volume of 7,581,113 shares. DexCom has a 12 month low of $47.92 and a 12 month high of $96.38. The company’s market cap is $7.25 billion. The stock has a 50 day moving average of $64.83 and a 200 day moving average of $79.31.

COPYRIGHT VIOLATION NOTICE: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be read at http://www.dailypolitical.com/2017/01/13/canaccord-genuity-reaffirms-buy-rating-for-dexcom-inc-dxcm.html.

In related news, EVP Steven Robert Pacelli sold 10,300 shares of the business’s stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $81.95, for a total value of $844,085.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Andrew K. Balo sold 3,200 shares of the business’s stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $62.86, for a total value of $201,152.00. Following the completion of the sale, the executive vice president now owns 109,545 shares of the company’s stock, valued at approximately $6,885,998.70. The disclosure for this sale can be found here. 2.80% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. Fort Point Capital Partners LLC purchased a new stake in shares of DexCom during the third quarter worth about $2,454,000. ETRADE Capital Management LLC purchased a new stake in shares of DexCom during the third quarter worth about $284,000. LPL Financial LLC bought a new stake in DexCom during the third quarter worth $611,000. Credit Suisse AG raised its stake in DexCom by 93.1% in the third quarter. Credit Suisse AG now owns 103,455 shares of the medical device company’s stock worth $9,068,000 after buying an additional 49,867 shares in the last quarter. Finally, Verition Fund Management LLC bought a new stake in DexCom during the third quarter worth $593,000.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

5 Day Chart for NASDAQ:DXCM

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.